Clinical Trials Sponsored by Cancer Prevention Pharmaceuticals, Inc.

Total 456 results

M.D. Anderson Cancer Center
Genentech, Inc.; Millennium Pharmaceuticals, Inc.

Withdrawn

Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)

Lung Cancer
Rabin Medical Center
Provention Bio, Inc.

Recruiting

The Israeli Study for Islet Autoantibodies Screening in Families of Type-1 Diabetes Patients

Type 1 Diabetes

Israel
Sigma-Tau Research, Inc.
Colorado Prevention Center

Completed

Safety and Efficacy of Propionyl-L-Carnitine in the Treatment of Peripheral Arterial Disease (Intermittent Claudication)

Peripheral Vascular Diseases | Intermittent Claudication

United States
M.D. Anderson Cancer Center
ICN Pharmaceuticals

Completed

Intermittent Use of Aerosolized Ribavirin for Treatment of RSV

Hematological Malignancies

United States
Giselle Sholler
University of Arizona; Cancer Prevention Pharmaceuticals, Inc.; University of...

Completed

Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

Neuroblastoma

United States
Cantex Pharmaceuticals
Medpace, Inc.

Recruiting

Azeliragon in MGMT Unmethylated Glioblastoma

Glioblastoma

United States
Memorial Sloan Kettering Cancer Center
Agios Pharmaceuticals, Inc.

Recruiting

AG-120 in People With IDH1 Mutant Chondrosarcoma

Chondrosarcoma | IDH1 Gene Mutation | Chondrosarcoma, Grade 2 | Chondrosarcoma, Grade 3

United States
Memorial Sloan Kettering Cancer Center
Progenics Pharmaceuticals, Inc.

Recruiting

Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate Neoplasm

United States
Memorial Sloan Kettering Cancer Center
Spectrum Pharmaceuticals, Inc

Active, not recruiting

Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.

Multiple Myeloma | Amyloidosis

United States
Memorial Sloan Kettering Cancer Center
BeyondSpring Pharmaceuticals Inc.

Active, not recruiting

Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
Aragon Pharmaceuticals, Inc.

Completed

ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

Prostate Cancer

United States
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.; Pharmatech

Completed

Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan

Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

Metastatic Castration-Resistant Prostate Cancer

United States
M.D. Anderson Cancer Center
Genentech, Inc.; OSI Pharmaceuticals

Completed

FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years

Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
Bayer; Astex Pharmaceuticals, Inc.

Terminated

Alemtuzumab and Pentostatin In T-cell Neoplasms

Lymphoma | Leukemia

United States
Vanderbilt-Ingram Cancer Center
Astex Pharmaceuticals, Inc.; Forma Therapeutics, Inc.

Withdrawn

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome
Memorial Sloan Kettering Cancer Center
Astex Pharmaceuticals, Inc.

Recruiting

A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

Malignant Peripheral Nerve Sheath Tumors (MPNST)

United States
Memorial Sloan Kettering Cancer Center
Millennium Pharmaceuticals, Inc.

Active, not recruiting

Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study

Multiple Myeloma | High Risk Smoldering Multiple Myeloma

United States
M.D. Anderson Cancer Center
Genentech, Inc.; OSI Pharmaceuticals

Completed

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

Liver Cancer

United States
Fox Chase Cancer Center
Genentech, Inc.; OSI Pharmaceuticals

Completed

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States
Memorial Sloan Kettering Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D

Non-Small Cell Lung Cancer

United States
Memorial Sloan Kettering Cancer Center
Progenics Pharmaceuticals, Inc.

Completed

Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
Mirna Therapeutics, Inc.
Cancer Prevention Research Institute of Texas

Terminated

A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

Melanoma | Lymphoma | Renal Cell Carcinoma | Multiple Myeloma | NSCLC | Primary Liver Cancer | SCLC

Korea, Republic of, United States
Jonsson Comprehensive Cancer Center
Genentech, Inc.; Aventis Pharmaceuticals

Completed

Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer

Breast Cancer

United States
Memorial Sloan Kettering Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

Amyloidosis | Light Chain Deposition Disease (LCDD or MIDD) | Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD) | Monoclonal Immunoglobulin Deposition Disease (MIDD)

United States
M.D. Anderson Cancer Center
Genentech, Inc.; Aventis Pharmaceuticals

Completed

Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Cancer

United States
Masonic Cancer Center, University of Minnesota
Novartis Pharmaceuticals; Millennium Pharmaceuticals, Inc.

Terminated

Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

Pancreatic Cancer

United States
M.D. Anderson Cancer Center
TAP Pharmaceutical Products Inc.

Completed

GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients

Amenorrhea | Premature Ovarian Failure | Ovarian Function Insufficiency

United States
M.D. Anderson Cancer Center
TAP Pharmaceutical Products Inc.

Withdrawn

Reflux Disease in Head and Neck Cancer Patients Undergoing Radiation Therapy

Head and Neck Cancer | Gastroesophageal Reflux Disease | Oropharyngeal Cancer
UNC Lineberger Comprehensive Cancer Center
Syndax Pharmaceuticals

Completed

An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma

Melanoma

United States
UNC Lineberger Comprehensive Cancer Center
Bellicum Pharmaceuticals

No longer available

Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

Immune System Diseases | Immunoproliferative Disorders | Acute Lymphoblastic Leukemia

United States
UNC Lineberger Comprehensive Cancer Center
Peregrine Pharmaceuticals

Completed

Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects

Non Small Cell Lung Cancer (NSCLC)

United States
UNC Lineberger Comprehensive Cancer Center
Aventis Pharmaceuticals

Completed

Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC

Lung Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Bellicum Pharmaceuticals

Not yet recruiting

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Breast Cancer | Triple Negative Breast Cancer | Relapse | Resistant Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Novartis Pharmaceuticals

Completed

Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Novartis Pharmaceuticals

Completed

A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases

HER-2 Positive Breast Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Novartis Pharmaceuticals

Completed

Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Advanced Adult Hepatocellular Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Millennium Pharmaceuticals, Inc.; Karyopharm Therapeutics Inc

Completed

A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma

Multiple Myeloma | Relapsed and/or Refractory Multiple Myeloma

United States
Ohio State University Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade... and other conditions

United States
Ohio State University Comprehensive Cancer Center
Astex Pharmaceuticals, Inc.

Completed

Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia

B-Chronic Lymphocytic Leukemia

United States
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC; Millennium Pharmaceuticals, Inc.; Ortho Biotech, Inc.

Terminated

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Spectrum Pharmaceuticals, Inc

Active, not recruiting

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

EGFR Exon 20 Mutation | ERBB2 Gene Mutation | Recurrent Lung Non-Small Cell Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Completed

Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone

Prostate Cancer

United States
Masonic Cancer Center, University of Minnesota
Millennium Pharmaceuticals, Inc.

Terminated

Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders

Lymphoproliferative Disorder

United States
M.D. Anderson Cancer Center
Schering-Plough; Enzon Pharmaceuticals, Inc.

Terminated

DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis

Neoplastic Meningitis

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Cyclacel Pharmaceuticals, Inc.

Terminated

Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)

Leukemia

United States
Masonic Cancer Center, University of Minnesota
Millennium Pharmaceuticals, Inc.

Terminated

Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

United States
University of Michigan Rogel Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma

Neuroblastoma

United States
M.D. Anderson Cancer Center
Novartis Pharmaceuticals; BTG International Inc.

Withdrawn

Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease

Liver Cancer
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Astex Pharmaceuticals, Inc.

Recruiting

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive | BCR-ABL1 Positive Chronic Myelogenous Leukemia | BCR-ABL1 Positive

United States

Clinical Trials Sponsored by Cancer Prevention Pharmaceuticals, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations